Abstract:Objective The study is aimed to learn the influence of rapamycin on the sensitivity of cisplatin in ovarian cancer cell lines, and to investigate the relationship between the mTOR signaling pathway and cisplatin-resis-tance in ovarian cancer cell lines, besides, the molecular mechanism of the cytotoxic effects of rapamycin on ovarian cancer cell lines is preliminarily explored. Method The resistance index (RI) and cell proliferation inhibition rate were analyzed by CCK-8 assay. After the administration of different therapies, the influence of colony formation on the two cell lines were evaluated with clone tablet experiment. The different expression of proteins in both cell lines were detected using Western blot. Result 1) The RI of SKOV3/DDP cell line was 6.10, indicating a moderate resis-tance to cisplatin. 2) In SKOV3 cell line, the cell proliferation inhibition rate of combined therapy groups were signif-icantly higher than that of cisplatin groups after treatment for 24 h and 48 h (P<0.01), while there was no statistical difference after 72 h treatment (P>0.05). In SKOV3/DDP cell line, the cell proliferation inhibition rates of combined therapy groups were significantly higher compared to cisplatin groups in 24 h, 48 h, 72 h, with statistically significant difference (P<0.01). 3) In SKOV3 cell line, when cells were incubated with cisplatin + rapamycin for 4h, the colo-ny formation inhibition rate was significantly higher when compared with the cisplatin groups (P <0.01). 4)Gray-scale analysis showed that p-mTOR and p-AKT were overexpressed in SKOV3/DDP, while mTOR, AKT had similar ex-pression. 5) Rapamycin + cisplatin had more cleavage than cisplatin groups. 6) SKOV3 cell line had a decreased ex-pression of BCL2, and an increased transformation from LC3BI to LC3BII when treated with rapamycin for 24 hours; And those were not observed in SKOV3/DDP cell line. Conclusion 1) In vitro, rapamycin can enhance the chemosensitivity of SKOV3 and SKOV3/DDP cell lines to cisplatin. 2) The activation of the mTOR pathway may play an important role in the development of cisplatin-resistance. 3) Rapamycin increases the chemosensitivity of SKOV3 cell line to cisplatin, of which the underlying molecular mechanisms may include: enhancement of cisplatin-induced DNA cleavage, downregulation of BCL2 and induce of autophagy, while the mechanisms involved in SKOV3/DDP cell line only include the enhancement of cisplatin-induced DNA cleavage.

Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

FUT4siRNA Augments the Chemosensitivity of Non-Small Cell Lung Cancer to Cisplatin Through Activation of FOXO1-induced Apoptosis.

Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells

Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells

MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway

Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

The negative feedback between miR‐143 and DNMT3A regulates cisplatin resistance in ovarian cancer

miR-185-5p rewires cisplatin resistance by restoring miR- 203a-3p expression via downregulation of SOX9

The role of microRNA in cisplatin resistance or sensitivity

Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro

Proteomics Analysis Revealed Smad3 As a Potential Target of the Synergistic Antitumor Activity of Disulfiram and Cisplatin in Ovarian Cancer.

Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop

Mechanism of rapamycin increasing the chemosensitivity of ovarian cancer cell lines to cisplatin

The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer

Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling

Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity